FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108862616> ?p ?o ?g. }

• W2108862616 endingPage "433" @default.
• W2108862616 startingPage "432" @default.
• W2108862616 abstract "We read the recent publications of Ychou et al. [1.Ychou M. Raoul J.L. Douillard J.Y. et al.A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).Ann Oncol. 2009; 20: 674-680Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar, 2.Ychou M. Hohenberger W. Thezenas S. et al.A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.Ann Oncol. 2009; 20: 1964-1970Abstract Full Text Full Text PDF PubMed Scopus (190) Google Scholar] on ‘adjuvant’ irinotecan-based chemotherapy in high-risk localized colorectal cancer (CRC) and after resection of liver-confined metastatic disease with great interest. In contrast to the improved outcome provided by oxaliplatin-based adjuvant treatment of early-stage disease, there is now a body of evidence showing that the addition of irinotecan to 5-fluorouracil (5-FU)/Leucovorin does not provide a benefit in this setting [1.Ychou M. Raoul J.L. Douillard J.Y. et al.A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).Ann Oncol. 2009; 20: 674-680Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar, 3.Van Cutsem E. Labianca R. Bodoky G. et al.Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETAAC-3.J Clin Oncol. 2009; 27: 3117-3125Crossref PubMed Scopus (365) Google Scholar]. The authors are to be congratulated for reporting the largest randomized trial of adjuvant treatment after resected colorectal liver metastases. Such trials have been historically difficult to accrue and it has been hard to show an overall survival benefit with either systemic or regional treatment in this setting. On the basis of data, we are now pretty sure that the conclusion from the localized disease setting—only combination of 5-FU with oxaliplatin confers an advantage over 5-FU alone—can also be applied to liver-confined resectable CRC as has already been common practice in most centers. It is a commonly uttered wish that future clinical trials should stratify patients according to their particular risk as well as biomarkers predicting response to treatment. Resectable metastatic CRC would lend itself to such a strategy as the postoperative recovery period leaves several weeks to do the ‘molecular homework’. Despite groundbreaking work in colon cancer assessing the role of topoisomerase I, thymidylate synthase and excision repair cross-complementation group in predicting response to irinotecan, 5-FU and oxaliplatin, respectively, practice-changing trials are still at large. DNA mismatch repair (MMR) defects, in contrast, are easily assessed by immunohistochemistry and may provide important information regarding efficacy of irinotecan [4.Bertagnolli M.M. Niedzwiecki D. Compton C.C. et al.Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.J Clin Oncol. 2009; 27: 1814-1821Crossref PubMed Scopus (306) Google Scholar]. We are interested to know whether Ychou et al. assessed tumor tissue for DNA MMR defects or microsatellite instability (MSI). Patients who can undergo curative resection of liver metastases have an outcome that lies somewhere between that for patients with stage IIIB–IIIC disease. MMR status may, therefore, be of relevance for this group. We acknowledge that MMR loss is an uncommon event in sporadic advanced CRC (<10%) [5.Koopman M. Kortman G.A. Mekenkamp L. et al.Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.Br J Cancer. 2009; 100: 266-273Crossref PubMed Scopus (304) Google Scholar] and recent data from a large adjuvant trial for early-stage disease have shown that MSI, a surrogate for MMR protein loss, was less common in stage III and was not independently prognostic of outcome (relapse-free survival and overall survival) [6.Roth AD, Tejpar S, Yan P, et al. Stage-specific prognostic value of molecular markers in colon cancer: results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. In Proceedings of the American Society of Clinical Oncology Annual Meeting, Chicago, IL, 29 May–2 June 2009 (Abstr 4002). 2009.Google Scholar]. However, there are little data on the potential role of MMR loss as a biomarker post-liver resection and chemotherapy trials in this setting are lacking. One of the difficulties inherent to accrual for adjuvant trials is likely explained by the reluctance of patients and physicians alike to consider a surgery-alone arm after liver resection. The validation of biomarkers such as MMR loss, even in small subsets of patients, may make a surgery-alone arm more attractive, improve accrual and may identify a population who will benefit most from adjuvant therapy. In concordance with the authors, we also feel that ‘considerations for tailoring combination therapies in the adjuvant treatment of liver-limited CRC to patients who will receive most benefit will need to be integrated into future trials’. Response to oxaliplatin-based treatment may also be different in tumors that harbor MMR defects [7.Muller C.I. Schulmann K. Reinacher-Schick A. et al.Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group.Int J Colorectal Dis. 2008; 23: 1033-1039Crossref PubMed Scopus (64) Google Scholar]. The authors have no conflict of interest to declare." @default.
• W2108862616 created "2016-06-24" @default.
• W2108862616 creator A5035051777 @default.
• W2108862616 creator A5055522939 @default.
• W2108862616 date "2010-02-01" @default.
• W2108862616 modified "2023-09-29" @default.
• W2108862616 title "Irinotecan and mismatch repair deficiency" @default.
• W2108862616 cites W1992151729 @default.
• W2108862616 cites W2052228812 @default.
• W2108862616 cites W2121113526 @default.
• W2108862616 cites W2159342260 @default.
• W2108862616 cites W2160550688 @default.
• W2108862616 cites W2165900465 @default.
• W2108862616 cites W2992480873 @default.
• W2108862616 doi "https://doi.org/10.1093/annonc/mdp550" @default.
• W2108862616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19940003" @default.
• W2108862616 hasPublicationYear "2010" @default.
• W2108862616 type Work @default.
• W2108862616 sameAs 2108862616 @default.
• W2108862616 citedByCount "0" @default.
• W2108862616 crossrefType "journal-article" @default.
• W2108862616 hasAuthorship W2108862616A5035051777 @default.
• W2108862616 hasAuthorship W2108862616A5055522939 @default.
• W2108862616 hasBestOaLocation W21088626161 @default.
• W2108862616 hasConcept C121608353 @default.
• W2108862616 hasConcept C126322002 @default.
• W2108862616 hasConcept C143998085 @default.
• W2108862616 hasConcept C2777982462 @default.
• W2108862616 hasConcept C2779804826 @default.
• W2108862616 hasConcept C2780259306 @default.
• W2108862616 hasConcept C2780456651 @default.
• W2108862616 hasConcept C526805850 @default.
• W2108862616 hasConcept C71924100 @default.
• W2108862616 hasConceptScore W2108862616C121608353 @default.
• W2108862616 hasConceptScore W2108862616C126322002 @default.
• W2108862616 hasConceptScore W2108862616C143998085 @default.
• W2108862616 hasConceptScore W2108862616C2777982462 @default.
• W2108862616 hasConceptScore W2108862616C2779804826 @default.
• W2108862616 hasConceptScore W2108862616C2780259306 @default.
• W2108862616 hasConceptScore W2108862616C2780456651 @default.
• W2108862616 hasConceptScore W2108862616C526805850 @default.
• W2108862616 hasConceptScore W2108862616C71924100 @default.
• W2108862616 hasIssue "2" @default.
• W2108862616 hasLocation W21088626161 @default.
• W2108862616 hasLocation W21088626162 @default.
• W2108862616 hasLocation W21088626163 @default.
• W2108862616 hasLocation W21088626164 @default.
• W2108862616 hasOpenAccess W2108862616 @default.
• W2108862616 hasPrimaryLocation W21088626161 @default.
• W2108862616 hasRelatedWork W134396366 @default.
• W2108862616 hasRelatedWork W1970193197 @default.
• W2108862616 hasRelatedWork W2003872607 @default.
• W2108862616 hasRelatedWork W2010991676 @default.
• W2108862616 hasRelatedWork W2017550036 @default.
• W2108862616 hasRelatedWork W2034983765 @default.
• W2108862616 hasRelatedWork W2069668461 @default.
• W2108862616 hasRelatedWork W2138090660 @default.
• W2108862616 hasRelatedWork W2363674970 @default.
• W2108862616 hasRelatedWork W4210563422 @default.
• W2108862616 hasVolume "21" @default.
• W2108862616 isParatext "false" @default.
• W2108862616 isRetracted "false" @default.
• W2108862616 magId "2108862616" @default.
• W2108862616 workType "article" @default.